Ion Beam Applications S.A.

IBA- Ion Beam Applications develops and markets technologies and pharmaceutical products for the healthcare sector, with a focus on cancer diagnosis and therapy. Co. is also engaged in the sterilization and ionization market. Co. operates in two primary business segments: Equipment and Pharmaceuticals. Co.'s Equipment segment encompasses development, fabrication, and services associated with medical and industrial particle accelerators, proton therapy systems, and a range of dosimetry products, while Co.'s Pharmaceuticals segment encompasses the production and distribution of radiopharmaceutical agents as well as its bioassay operations.
  • TickerIBAB
  • ISINBE0003766806
  • ExchangeEuronext Brussels
  • SectorHealth Care Equipment & Services
  • CountryBelgium

Analysts

ING
ING Helpdesk

Benelux Morning Notes

AMG: Taking a next step in Lithium. EVS: Profit warning, sales guidance narrowed to €100-110m. IBA: Guidance reiterated on backlog conversion in PT, strong “Other accelerators” sales. KBC: Delivering another strong set of results. Kinepolis: Strong Q3 visitor numbers bode well for 2019. NN Group: Headline beat masks weak Dutch Life performance. SBM Offshore: Guidance up, remains disciplined.

Bart Cuypers ...
  • Cedric Duinslaeger
  • Guy Sips
  • Jan Opdecam
  • Jason Kalamboussis
  • Lenny Van Steenhuyse
  • Ruben Devos
  • Sandra Cauwenberghs
  • Thomas Couvreur
  • Wido Jongman

Morning Note: ADYEN NA, BCART BB, EVS BB, FLUX BB, IBAB BB, IVA FP, KIN BB, NN NA, PROX BB, QRF BB, SBMO NA, VGP BB

Adyen: Issuing an upgrade Biocartis: High 4Q19 cartridge volume hopes EVS: Lower guidance for FY19 Fluxys Belgium: Christian Leclercq to become new CFO IBA: High revenue – low margin narrative continues Inventiva: 3Q19 update: Boehringer collaboration ended Kinepolis: Storing 3Q19 : content and no world cup football NN Group: Solid 3Q underlying, low divi upstream Proximus: Downgrade to REDUCE Qrf: 3Q19 results in line with estimates SBM Offshore: A well-oiled machine, increases FY guidance VGP: Positive 10M19 trading update

ING
ING Helpdesk

Benelux Morning Notes

Arcadis: Cash flow delay hurts; results good. BESI: Another nice beat despite the industry downturn. Core Laboratories: As expected 3Q19 results. DWS: Focus on NNM and cost efficiency. Euronext: 3Q19F results – focus on fully consolidated Oslo impact. IBA: Competitor Varian sells compact PT unit in the US and reports 4Q19. Marel: 3Q arrives bang in line, solid execution

ING
ING Helpdesk

Benelux Morning Notes

a.s.r.: CFO resigns to become CFO of KPN. IBA: Receives downpayment for the €90m ProteusPLUS contract in Shenzhen, China. KPN: New CEO, CFO and expansion of the Management Board. PostNL: agreement on Sandd take-over reached; phasing cost savings more favourable

Tolu Alamutu CFA

International Bank of Azerbaijan: Unfinished business

Our Hold recommendation on the International Bank of Azerbaijan (IBAZAZ) 3.5% 2024 bond is unchanged. IBAZAZ has been refused the right to appeal previous judgements upholding the rights of certain holders of the IBAZAZ 5.625% 2019 bond by the UK Supreme Court. This is according to a press release issued by Dechert, the law firm representing the bondholders. As we have previously noted, the bondholders’ claim relied on an 1890 precedent, known as the Gibbs case. The press release disclosed a claim of ‘more than US$170 million’ now due to bondholders. This compares with the total amount issued ...

ING
ING Helpdesk

Benelux Morning Notes

AMG: Taking a next step in Lithium. EVS: Profit warning, sales guidance narrowed to €100-110m. IBA: Guidance reiterated on backlog conversion in PT, strong “Other accelerators” sales. KBC: Delivering another strong set of results. Kinepolis: Strong Q3 visitor numbers bode well for 2019. NN Group: Headline beat masks weak Dutch Life performance. SBM Offshore: Guidance up, remains disciplined.

Bart Cuypers ...
  • Cedric Duinslaeger
  • Guy Sips
  • Jan Opdecam
  • Jason Kalamboussis
  • Lenny Van Steenhuyse
  • Ruben Devos
  • Sandra Cauwenberghs
  • Thomas Couvreur
  • Wido Jongman

Morning Note: ADYEN NA, BCART BB, EVS BB, FLUX BB, IBAB BB, IVA FP, KIN BB, NN NA, PROX BB, QRF BB, SBMO NA, VGP BB

Adyen: Issuing an upgrade Biocartis: High 4Q19 cartridge volume hopes EVS: Lower guidance for FY19 Fluxys Belgium: Christian Leclercq to become new CFO IBA: High revenue – low margin narrative continues Inventiva: 3Q19 update: Boehringer collaboration ended Kinepolis: Storing 3Q19 : content and no world cup football NN Group: Solid 3Q underlying, low divi upstream Proximus: Downgrade to REDUCE Qrf: 3Q19 results in line with estimates SBM Offshore: A well-oiled machine, increases FY guidance VGP: Positive 10M19 trading update

ING
ING Helpdesk

Benelux Morning Notes

Arcadis: Cash flow delay hurts; results good. BESI: Another nice beat despite the industry downturn. Core Laboratories: As expected 3Q19 results. DWS: Focus on NNM and cost efficiency. Euronext: 3Q19F results – focus on fully consolidated Oslo impact. IBA: Competitor Varian sells compact PT unit in the US and reports 4Q19. Marel: 3Q arrives bang in line, solid execution

ING
ING Helpdesk

Benelux Morning Notes

a.s.r.: CFO resigns to become CFO of KPN. IBA: Receives downpayment for the €90m ProteusPLUS contract in Shenzhen, China. KPN: New CEO, CFO and expansion of the Management Board. PostNL: agreement on Sandd take-over reached; phasing cost savings more favourable

Cedric Duinslaeger ...
  • Lenny Van Steenhuyse
  • Ruben Devos

Morning Note: EXM BB, IBAB BB, KPN NA, PNL NA, VPK NA

EXMAR: Update on Sinosure, CSSC, TFLNG and LPG market IBA: Finalization of Shenzhen contract KPN: New CEO and CFO / expansion of Board of Mgmt PostNL: Update on transaction elements Sandd Vopak: Completion Amsterdam/Hamburg assets

1 director sold

A director at IBA sold 1,250 shares at 16.790EUR and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board members alo...

An increasingly favourable environment allows ION BEAM APPLICATIONS SA to improve to Neutral

The independent financial analyst theScreener just upgraded the general evaluation of ION BEAM APPLICATIONS SA (BE), a company active in the Medical Equipment industry. As regards its fundamental valuation, the title confirms its rating of 3 out of 4 stars while its market behaviour remains as risky. theScreener believes, however, that a more enabling environment allows the title to increase its general evaluation to Neutral. As of the analysis date August 23, 2019, the closing price was EUR 17.28 and its expected value was estimated at EUR 15.78.

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch